-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Opinion|Videos|January 20, 2025

Unmet Needs With Recurrent C Difficile Infections

The panelist discusses how recurrent Clostridioides difficile infections represent a critical health care challenge, characterized by unmet needs in long-term prevention, microbiome restoration, and personalized treatment. The field is evolving toward precision medicine approaches, leveraging advanced diagnostics, innovative therapeutic modalities such as engineered probiotics and bacteriophage therapies, and comprehensive strategies that integrate microbial, immunological, and genetic insights to improve patient outcomes.

Video content above is prompted by the following:

What are the main unmet needs for recurrent C difficile infections and how do you see the field evolving in the future?


Related to this article

Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel.  | Image: LinkedIn
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.